Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Among authors: bertocci e. Cancer Immunol Immunother. 2013 Jun;62(6):1021-8. doi: 10.1007/s00262-013-1418-6. Epub 2013 Apr 17. Cancer Immunol Immunother. 2013. PMID: 23591982 Free PMC article.
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.
Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT. Maio M, et al. Among authors: bertocci e. Cancer Immunol Immunother. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. Cancer Immunol Immunother. 2016. PMID: 25944004 Free PMC article. No abstract available.
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Among authors: bertocci e. Cancer Immunol Immunother. 2011 Apr;60(4):467-77. doi: 10.1007/s00262-010-0958-2. Epub 2010 Dec 18. Cancer Immunol Immunother. 2011. PMID: 21170646 Free PMC article. Clinical Trial.
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.
Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Giacobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G; NIBIT. Maio M, et al. Among authors: bertocci e. Cancer Immunol Immunother. 2016 Nov;65(11):1423-1431. doi: 10.1007/s00262-016-1899-1. Epub 2016 Sep 12. Cancer Immunol Immunother. 2016. PMID: 27619513 Free PMC article. No abstract available.
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13-15, 2016.
Russo V, Chiarucci C, Lofiego MF, Fazio C, Bertocci E, Cutaia O, Giacobini G, Lazzeri A, Lamboglia A, Altomonte M, Tunici P, Covre A, Maio M. Russo V, et al. Among authors: bertocci e. Cancer Immunol Immunother. 2018 Jun;67(6):1023-1030. doi: 10.1007/s00262-017-2078-8. Epub 2017 Oct 20. Cancer Immunol Immunother. 2018. PMID: 29058034 Free PMC article. No abstract available.
Haptoglobin phenotypes in systemic sclerosis.
Giordano N, Guerranti R, Bertocci E, Papakostas P, Rollo F, Figura N, Leoncini R, Pagani R, Nuti R. Giordano N, et al. Among authors: bertocci e. Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1162. Clin Exp Rheumatol. 2008. PMID: 19210891 No abstract available.
14 results